| Literature DB >> 30728152 |
Il-Kyu Kim1,2, Choong-Hyun Koh1, Insu Jeon2, Kwang-Soo Shin1, Tae-Seung Kang2, Eun-Ah Bae2, Hyungseok Seo2, Hyun-Ja Ko3,4, Byung-Seok Kim5, Yeonseok Chung5, Chang-Yuil Kang6,2.
Abstract
GM-CSF as an adjuvant has been shown to promote antitumor immunity in mice and humans; however, the underlying mechanism of GM-CSF-induced antitumor immunity remains incompletely understood. In this study, we demonstrate that GM-CSF potentiates the efficacy of cancer vaccines through IL9-producing Th (Th9) cells. GM-CSF selectively enhanced Th9 cell differentiation by regulating the COX2-PGE2 pathway while inhibiting the differentiation of induced regulatory T (iTreg) cells in vitro and in vivo GM-CSF-activated monocyte-derived dendritic cells converted tumor-specific naïve Th cells into Th9 cells, and delayed tumor growth by inducing antitumor CTLs in an IL9-dependent manner. Our findings reveal a mechanism for the adjuvanticity of GM-CSF and provide a rationale for the use of GM-CSF in cancer vaccines. ©2019 American Association for Cancer Research.Entities:
Mesh:
Substances:
Year: 2019 PMID: 30728152 DOI: 10.1158/2326-6066.CIR-18-0518
Source DB: PubMed Journal: Cancer Immunol Res ISSN: 2326-6066 Impact factor: 11.151